GSK to invest $30 billion in US R&D and production

UK pharma major GSK (LSE: GSK) today announced plans to invest $30 billion across the USA in research and development and supply chain infrastructure over the next five years, adding to the string of major drugmakers announcing multibillion-dollar US projects in recent months.

GSK’s plan includes a new $1.2 billion investment in advanced manufacturing facilities and AI and advanced digital technologies, to deliver new, next-generation biopharma factories and laboratories in the United States. These investments build on GSK’s strong innovation and manufacturing footprint and capabilities in the USA today, developing and making products in the USA for the country

GSK sources insisted the investment plan did not equate to a “no confidence” vote in the UK.”